CCS is actively monitoring and responding to the recommendations of the Public Health Agency of Canada regarding coronavirus disease (COVID-19).
Dr Philippe Bedard
William E. Rawls Prize, 2017 recipient
Dr Philippe Bedard is a medical oncologist who is changing the landscape of personalized cancer medicine in Canada. His leadership of innovative clinical trials matching cancer therapies to the molecular features of individual tumours is changing how cancer is treated.
One of his many achievements has been the establishment and co-leadership of a molecular profiling program designed to map the abnormalities present in patients’ advanced solid tumours to fulfill the promise of personalized cancer medicine. This program has tested hundreds of cancer genes in tumour samples from thousands of patients, delivering results rapidly to guide personalized treatment decisions. It has now been expanded across Ontario, and Dr Bedard has spearheaded 2 trials to evaluate whether the program improves patient care.
Dr Bedard performs many clinical trials in breast cancer, as well as early phase trials of innovative new treatments in humans. He has deep expertise in complex trials combining multiple targeted drugs or immunotherapies. Collectively, these trials are providing key evidence on the safety, benefits and limitations of targeted or personalized cancer therapy.
Dr Bedard is recognized internationally as a leader in cancer genomics and an excellent mentor for the clinical researchers of tomorrow. By evaluating the safety and efficacy of new treatments and incorporating molecular profiling into routine care, Dr Bedard is making major contributions to advancing cancer control in Canada and beyond.
What’s the lifetime risk of getting cancer?
The latest Canadian Cancer Statistics report shows about half of Canadians are expected to be diagnosed with cancer in their lifetime.